CD3 Antibody and IL‐2 Complex Combination Therapy Inhibits Atherosclerosis by Augmenting a Regulatory Immune Response

BACKGROUND: Accumulating evidence suggests that the balance between pathogenic effector T cells (Teffs) and regulatory T cells (Tregs) may be important for controlling atherosclerotic disease. We hypothesized that a combination therapy with anti‐CD3 antibody (CD3‐Ab) and IL‐2/anti‐IL‐2 monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasahara, Kazuyuki, Sasaki, Naoto, Yamashita, Tomoya, Kita, Tomoyuki, Yodoi, Keiko, Sasaki, Yoshihiro, Takeda, Masafumi, Hirata, Ken‐ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187475/
https://www.ncbi.nlm.nih.gov/pubmed/24755152
http://dx.doi.org/10.1161/JAHA.113.000719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187475/
https://www.ncbi.nlm.nih.gov/pubmed/24755152
http://dx.doi.org/10.1161/JAHA.113.000719

Ejemplares similares